Dystrophin Expressing Chimeric (DEC) Cell Therapy for Duchenne Muscular Dystrophy: A First-in-Human Study with Minimum 6 Months Follow-up
-
Published:2023-03-31
Issue:5
Volume:19
Page:1340-1359
-
ISSN:2629-3269
-
Container-title:Stem Cell Reviews and Reports
-
language:en
-
Short-container-title:Stem Cell Rev and Rep
Author:
Heydemann Ahlke, Bieganski Grzegorz, Wachowiak Jacek, Czarnota Jarosław, Niezgoda Adam, Siemionow Krzysztof, Ziemiecka Anna, Sikorska Maria H., Bozyk Katarzyna, Tullius Stefan G., Siemionow MariaORCID
Abstract
AbstractDuchenne Muscular Dystrophy (DMD) is a X-linked progressive lethal muscle wasting disease for which there is no cure. We present first-in-human study assessing safety and efficacy of novel Dystrophin Expressing Chimeric (DEC) cell therapy created by fusion of patient myoblasts with myoblasts of normal donor origin. We report here on safety and functional outcomes of the first 3 DMD patients. No study related adverse events (AE) and no serious adverse events (SAE) were observed up to 14 months after systemic-intraosseous administration of DEC01. Ambulatory patients showed improvements in functional tests (6-Minute Walk Test (6MWT), North Star Ambulatory Assessment (NSAA)) and both, ambulatory and non-ambulatory in PUL, strength and fatigue resistance which correlated with improvement of Electromyography (EMG) parameters. DEC01 therapy does not require immunosuppression, involves no risks of off target mutations, is not dependent upon the causative mutation and is therefore a universal therapy that does not use viral vectors and therefore can be readministered, if needed. This study was approved by the Bioethics Committee (approval No. 46/2019).
Graphical Abstract
Mechanism of action of the Dystrophin Expressing Chimeric Cell (DEC) cells created via ex vivo fusion of human myoblast from normal and DMD-affected donors. Following systemic-intraosseous administration, DEC engraft and fuse with the myoblasts of DMD patients, deliver dystrophin and improve muscle strength and function. (Created with BioRender.com)
Publisher
Springer Science and Business Media LLC
Reference60 articles.
1. Van Ruiten, H. J. A., Marini Bettolo, C., Cheetham, T., Eagle, M., Lochmuller, H., Straub, V., … Guglieri, M. (2016). Why are some patients with Duchenne muscular dystrophy dying young: An analysis of causes of death in North East England. European Journal of Paediatric Neurology, 20(6), 904–909. https://doi.org/10.1016/j.ejpn.2016.07.020 2. Wahlgren, L., Kroksmark, A.-K., Tulinius, M., & Sofou, K. (2022). One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure. European Journal of Epidemiology, 37(2), 147–156. https://doi.org/10.1007/s10654-021-00819-4 3. Guiraud, S., Aartsma-Rus, A., Vieira, N. M., Davies, K. E., van Ommen, G.-J.B., & Kunkel, L. M. (2015). The Pathogenesis and Therapy of Muscular Dystrophies. Annual Review of Genomics and Human Genetics, 16(1), 281–308. https://doi.org/10.1146/annurev-genom-090314-025003 4. Bushby, K., Finkel, R., Birnkrant, D. J., Case, L. E., Clemens, P. R., Cripe, L., … Constantin, C. (2010). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology, 9(1), 77–93. https://doi.org/10.1016/S1474-4422(09)70271-6 5. Porcher, R., Desguerre, I., Amthor, H., Chabrol, B., Audic, F., Rivier, F., … Wahbi, K. (2021). Association between prophylactic angiotensin-converting enzyme inhibitors and overall survival in Duchenne muscular dystrophy—analysis of registry data. European Heart Journal, 42(20), 1976–1984. https://doi.org/10.1093/eurheartj/ehab054
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|